Research Article
Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer
Table 1
Demographic baseline clinical characteristics of women with metastatic breast cancer, ABLE Trial, Lyon, France, 2016-2018.
| | Baseline characteristics | All participants () |
| | Age (year), mean (SD) | 54.91 (10.41) | | Anthropometrics | | Height (m), mean (SD) | 1.62 (0.06) | | Weight (kg), mean (SD) | 69.12 (15.71) | | BMI (kg/m2), mean (SD) | 26.08 (5.78) | | Underweight (<18.5 kg/m2), (%) | 3 (6.1%) | | Normal weight (<25 kg/m2), (%) | 20 (40.8%) | | Overweight (25–30 kg/m2), (%) | 16 (32.7%) | | Obese (>30 kg/m2), (%) | 10 (20.4%) | | Clinical | | Number of metastatic localizations, (%) | 4.65 (3.05) | | De novo metastatic breast cancer, (%) | 14 (28.6%) | | Hormone therapy, n (%) | 27 (55.1%) | | Chemotherapy, (%) | 22 (44.9%) | | Histological subtype | | HER2+ | 1 (2.0%) | | Luminal A | 29 (59.2%) | | Luminal B | 6 (12.2%) | | Triple negative | 13 (26.5%) | | Number of metastatic locations | 4.65 (3.05) | | Metastatic locations | | Cerebral | 6 (12.2%) | | Bone | 33 (67.3%) | | Lung | 15 (30.6%) | | Nodes | 24 (49.0%) | | Skin | 1 (2.0%) | | Liver | 12 (24.5%) | | Other | 20 (40.8%) | | Blood count | | Hemoglobin (g/dL) | 12.88 (1.48) | | Creatinine (μmol/L) | 60.67 (11.79) | | Alanine aminotransferase (UI/L) | 25.39 (15.98) | | Aspartate aminotransferase (UI/L) | 28.51 (16.63) | | Alkaline phosphatase (UI/L) | 109.25 (82.40) | | Gamma-glutamyl transpeptidase (UI/L) | 71.58 (94.06) | | Comorbid conditions | | Cardiac disease | 17 (34.7%) | | Metabolic | 12 (24.5%) | | Respiratory | 4 (8.2%) | | Neurologic | 1 (2.0%) |
|
|
BMI: body mass index.
|
